바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

logo

메뉴

코로나바이러스(SARS-CoV-2)에 대한 구강 양치액의 효과: 주제 범위 문헌고찰

A scoping review on the effectiveness of mouth rinse against SARS-CoV-2

Abstract

Although studies reporting the efficacy of mouth rinse against SARS-CoV-2 have been continuously published, it is chal lenging to select literature through qualitative meta-synthesis or quality assessment of the study. Therefore, this study aims to systematically review the efficacy of mouth rinse against SARS-CoV-2 using the scoping review method and to provide the latest information. Literature search on electronic databases (PubMed, Scopus, and Cochrane Trials) was conducted. After establishing liter ature inclusion and exclusion criteria, two independent researchers were selected literatures. Of the 15 articles were included in this scoping review, 11 were in vitro studies, and four were in vivo studies. The ingredients tested in these studies were povidone-iodine, chlorhexidine, hydrogen peroxide, essential oils, and qua ternary ammonium compounds, and they showed various efficacy against SARS-CoV-2. Despite the relatively limited evidence from the included studies, the use of mouth rinse has the potential to reduce the viral load of SARS-CoV-2. In particular, povidone-iodine is expected to be the most effective against SARS-CoV-2, given the evidence so far.

keywords
COVID-19, mouth rinse, povidone-iodine, SARS-CoV-2, virus

참고문헌

1.

1. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization, 2021.

2.

2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382(13):1199-1207.

3.

3. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. World Health Organization, 2021.

4.

4. Yoo JY, Dutra SVO, Fanfan D, et al. Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti. BMC Public Health 2020;20(1):1853.

5.

5. Fernandes LL, Pacheco VB, Borges L, et al. Saliva in the Diagnosis of COVID-19: A Review and New Research Directions. J Dent Res 2020;99(13):1435-1443.

6.

6. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect 2020;81(3):e48-e50.

7.

7. CDC. Guidance for Dental Settings. Centers for Disease Control and Prevention, 2020.

8.

8. ADA. ADA COVID-19 Risk Management Guidance. Australian Dental Association, 2020.

9.

9. O'Donnell VB, Thomas D, Stanton R, et al. Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. Function (Oxf) 2020;1(1):zqaa002.

10.

10. Retamal-Valdes B, Soares GM, Stewart B, et al. Effectiveness of a pre-procedural mouthwash in reducing bacteria in dental aerosols: randomized clinical trial. Braz Oral Res 2017;31:e21.

11.

11. Feres M, Figueiredo LC, Faveri M, et al. The effectiveness of a preprocedural mouthrinse containing cetylpyridinium chloride in reducing bacteria in the dental office. J Am Dent Assoc 2010;141(4):415-422.

12.

12. WHO. Considerations for the provision of essential oral health services in the context of COVID-19: Interim guidance. World health Organization, 2020.

13.

13. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018;169(7):467-473.

14.

14. Khalil H, Peters M, Godfrey CM, et al. An Evidence-Based Approach to Scoping Reviews. Worldviews Evid Based Nurs 2016;13(2):118-123.

15.

15. Hassandarvish P, Tiong V, Mohamed NA, et al. In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J 2020:1-4.

16.

16. Bidra AS, Pelletier JS, Westover JB, et al. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses. J Prosthodont 2020;29(7):599-603.

17.

17. Bidra AS, Pelletier JS, Westover JB, et al. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. J Prosthodont 2020;29(6):529-533.

18.

18. Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARSCoV-2, The Virus Causing COVID-19 Disease. Infect Dis Ther 2020;9(3):669-675.

19.

19. Jain A, Grover V, Singh C, et al. Chlorhexidine: An effective anticovid mouth rinse. J Indian Soc Periodontol 2021;25(1):86-88.

20.

20. Koch-Heier J, Hoffmann H, Schindler M, et al. Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX(®) and BacterX(®) Pro. Microorganisms 2021;9(3).

21.

21. Komine A, Yamaguchi E, Okamoto N, Yamamoto K. Virucidal activity of oral care products against SARS-CoV-2 in vitro. J Oral Maxillofac Surg Med Pathol 2021;33(4):475-477.

22.

22. Seneviratne CJ, Balan P, Ko KKK, et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection 2021;49(2):305-311.

23.

23. Davies K, Buczkowski H, Welch SR, et al. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes. J Gen Virol 2021;102(4).

24.

24. Steinhauer K, Meister TL, Todt D, et al. Comparison of the in-vitro efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476. J Hosp Infect 2021;111:180-183.

25.

25. Eduardo FP, Corrêa L, Heller D, et al. Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial. Heliyon 2021;7(6):e07346.

26.

26. Huang YH, Huang JT. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients. J Med Virol 2021;93(7):4370-4373.

27.

27. Muñoz-Basagoiti J, Perez-Zsolt D, León R, et al. Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. J Dent Res 2021:220345211029269.

28.

28. Gottsauner MJ, Michaelides I, Schmidt B, et al. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. Clin Oral Investig 2020;24(10):3707-3713.

29.

29. Kawana R, Kitamura T, Nakagomi O, et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology 1997;195 Suppl 2:29-35.

30.

30. Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and non-enveloped viruses. J Hosp Infect 1998;38(4):283-295.

31.

31. Frank S, Capriotti J, Brown SM, Tessema B. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era. Ear Nose Throat J 2020;99(9):586-593.

32.

32. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Infect Dis Ther 2018;7(2):249-259.

33.

33. 이재관. 화학요법제(chemotherapeutic agents)를 이용한 비외과적치주치료. 대한치과의사협회지 2008;46:370-376.

34.

34. Addy M. Oral hygiene products: potential for harm to oral and systemic health? Periodontol 2000 2008;48:54-65.

35.

35. Horner C, Mawer D, Wilcox M. Reduced susceptibility to chlorhexidine in staphylococci: is it increasing and does it matter? J Antimicrob Chemother 2012;67(11):2547-2559.

36.

36. Van Strydonck DA, Slot DE, Van der Velden U, Van der Weijden F. Effect of a chlorhexidine mouthrinse on plaque, gingival inflammation and staining in gingivitis patients: a systematic review. J Clin Periodontol 2012;39(11):1042-1055.

37.

37. Bernstein D, SchiffG, Echler G, et al. In vitro virucidal effectiveness of a 0.12%-chlorhexidine gluconate mouthrinse. J Dent Res 1990;69(3):874-876.

38.

38. Rosling BG, Slots J, Webber RL, et al. Microbiological and clinical effects of topical subgingival antimicrobial treatment on human periodontal disease. J Clin Periodontol 1983;10(5):487-514.

39.

39. Bauroth K, Charles CH, Mankodi SM, et al. The efficacy of an essential oil antiseptic mouthrinse vs. dental floss in controlling interproximal gingivitis: a comparative study. J Am Dent Assoc 2003;134(3):359-365.

40.

40. Baker N, Williams AJ, Tropsha A, Ekins S. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19. Pharm Res 2020;37(6):104.

logo